What is Xention?
Xention is a biopharmaceutical company focused on the discovery and development of innovative ion channel-modulating drugs. The company's primary therapeutic focus is on atrial fibrillation, a condition with substantial unmet medical need. Xention leverages a proprietary approach to identify and design potent, selective small-molecule drugs, targeting key ion channels such as Kv1.5 and Kir3.1/3.4 (IKACh). These targets are recognized as novel and promising for atrial fibrillation treatment. The company has established collaborations with several industry partners, enhancing its research and development capabilities. Its strategic positioning in targeting specific ion channels for cardiovascular diseases highlights its specialized approach within the pharmaceutical sector.
How much funding has Xention raised?
Xention has raised a total of $44.9M across 4 funding rounds:
Series A
$5.7M
Series C
$6.5M
Series B
$20M
Series D
$12.7M
Series A (2003): $5.7M with participation from Albany Ventures, MVM Life Science Partners, BTG, and SPARK Ventures
Series C (2003): $6.5M led by MVM Life Science Partners and BTG International
Series B (2005): $20M supported by ABN AMRO Capital of Amsterdam, Cr�dit Agricole Private Equity, MVM, Enterprise VCT plc, Isis Equity Partners, Albany Ventures, BTG International, and Quester
Series D (2010): $12.7M featuring Seroba-Kernel Life Sciences Ltd
Key Investors in Xention
Seroba-Kernel Life Sciences Ltd
Seroba-Kernel Life Sciences Ltd is a European venture capital firm specializing in life sciences, with a focus on biotech and medtech innovations. Their deep industry and investment experience supports entrepreneurs in realizing ambitious goals.
ABN AMRO Capital of Amsterdam
ABN AMRO Capital is an investment arm likely focused on providing capital for growth and development across various sectors, including life sciences.
MVM Life Science Partners
MVM Life Science Partners is an investment firm dedicated to supporting companies in the life sciences sector, providing strategic capital and expertise to foster innovation and growth.
What's next for Xention?
The recent major strategic investment into Xention signals a critical phase of scaling and potentially advancing its pipeline candidates towards clinical trials. This substantial capital infusion, part of the overall $44.9M raised, will likely be directed towards accelerating drug development, expanding research infrastructure, and potentially forging new strategic alliances. The company's focus on ion channel modulation for atrial fibrillation positions it to address a significant market opportunity. Future growth will depend on the successful translation of its innovative drug discovery platform into tangible therapeutic solutions and navigating the complex regulatory pathways inherent in the pharmaceutical industry.
See full Xention company page
